Hyperkinetic syndrome of childhood (HKSoC) is a psychiatric disorder that is encompasses attention deficit disorder (ADD)/attention deficit hyperactive disorder (ADHD. The onset of HKSoC may be attributed to Thimerosal-persevered Hepatitis B vaccines due to the toxicological effects of the bolus exposure to organic-Hg (mercury). This hypothesis was formulated by vaccine safety researcher David Geier, along with fellow researchers, who recently published “Thimerosal-Preserved Hepatitis B Vaccine and Hyperkinetic Syndrome of Childhood” in the Brain Sciences journal of MDPI.
Geier and his fellow researchers noted that previous studies have implied that mercury exposure is a risk factor of the onset of HKSoC. To test the hypothesis, they used the Vaccine Safety Datalink to measure the toxicological effects of the bolus exposure to organic-Hg from Thimerosal-containing vaccines (TCVs) at varying levels and at specific intervals of time during the first six months after birth, and then evaluating the risk of a child being diagnosed with Hyperkinetic syndrome.
They found that a child was significantly more at risk of developing HKSoC when exposed to increasing doses of Thimerosal-persevered Hepatitis B vaccine within the first month (odds ratio = 1.45; 95% confidence interval = 1.30-1.62), within first two months (odds ratio = 1.43; 95% confidence interval = 1.28-1.59), and within the first six months (odds ratio = 4.51; 95% confidence interval = 3.04–6.71).
The researchers concluded that the results indicate a heightened risk of a HKSoC diagnosis when exposed to organic-Hg exposure from TCVs. This is a significant finding because the CDC’s recommended immunization schedule for children from birth to 6 years old makes the HepB vaccination the first one in an infant’s life, which the above research indicates serious repercussions following that specific vaccination.